Plerixafor: all 121 studies that test it

Page 1 of 2. Open to participants first (8), then studies with results posted, then the rest; newest registration first within each.

• Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIMEnrolling by invitationNCT07775313Phase 1/2
• Stem Cell Mobilization and Apheresis for Life-threatening Blood DisordersRecruitingNCT07585136Phase 1
• Mozobil for Autologous Hematopoietic Stem Cell TransplantationRecruitingNCT07188090Phase 2
• Allo HSCT for High Risk HemoglobinopathiesRecruitingNCT06872333Phase 2
• Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet DisorderRecruitingNCT06414889Phase 1
• Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous DiseaseRecruitingNCT06325709Phase 1/2
• Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal EndometriumRecruitingNCT05343572Early Phase 1
• Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine ModelsRecruitingNCT02015013Phase 2
• Study of MGTA-145 and Plerixafor in Patients With Sickle Cell DiseaseTerminatedNCT05445128Phase 2Results posted
• MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic MalignanciesTerminatedNCT04762875Phase 2Results posted
• MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple MyelomaCompletedNCT04552743Phase 2Results posted
• Plerixafor and Cemiplimab in Metastatic Pancreatic CancerCompletedNCT04177810Phase 2Results posted
• Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With GlioblastomaCompletedNCT03746080Phase 2Results posted
• Peripheral Blood Stem Cell Collection for Sickle Cell Disease (SCD) PatientsCompletedNCT03226691Phase 1Results posted
• Plerixafor Versus G-CSF in the Treatment of People With WHIM SyndromeCompletedNCT02231879Phase 2/3Results posted
• Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade GliomaCompletedNCT01977677Phase 1/2Results posted
• Plerixafor for Stem Cell Mobilization in Normal DonorsCompletedNCT01818284Phase 2Results posted
• A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous PlerixaforCompletedNCT01696461Phase 2Results posted
• T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic TransplantTerminatedNCT01621477Phase 2Results posted
• Collection of Transplant Stem Cells for Plasma Cell MyelomaCompletedNCT01547806Phase 2Results posted
• Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin LymphomaTerminatedNCT01408043Not applicableResults posted
• Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)CompletedNCT01373229Phase 1Results posted
• Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With LenalidomideTerminatedNCT01301963Phase 3Results posted
• Donor Enhancement With Plerixafor Post Myeloablative Allogeneic TransplantCompletedNCT01280955Phase 1/2Results posted
• Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 KilogramsCompletedNCT01164475Phase 4Results posted
• Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML)TerminatedNCT01160354Phase 1/2Results posted
• Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling DonorsCompletedNCT01158118Phase 2Results posted
• Alteration in Timing of Plerixafor AdministrationCompletedNCT01149863Phase 2Results posted
• Trial of Three Stem Cell Mobilization Regimens for Multiple MyelomaCompletedNCT01146834Phase 3Results posted
• Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem CellsCompletedNCT01097057Phase 2Results posted
• Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell CollectionCompletedNCT01095757Phase 2Results posted
• Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesTerminatedNCT01076270Not applicableResults posted
• AMD 3100 for Treatment of MyelokathexisCompletedNCT01058993Phase 1Results posted
• Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell TransplantCompletedNCT00998049Phase 2Results posted
• Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological MalignanciesCompletedNCT00914849Phase 2Results posted
• Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid LeukemiaCompletedNCT00906945Phase 1/2Results posted
• Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell TransplantCompletedNCT00901225Phase 2Results posted
• Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and ThymoglobulinCompletedNCT00822770Phase 1/2Results posted
• Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With LymphomaCompletedNCT00733824Phase 1/2Results posted
• AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid LeukemiaCompletedNCT00512252Phase 1/2Results posted
• Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100CompletedNCT00479115Phase 1/2Results posted
• Safety, Pharmacokinetics (PK), And Hematological Activity Of AMD3100 (Plerixafor) In Subjects With Renal ImpairmentCompletedNCT00445302Phase 1Results posted
• Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for TransplantationTerminatedNCT00396383Phase 2Results posted
• AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/AttemptsCompletedNCT00396331Phase 2Results posted
• AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSFCompletedNCT00396266Phase 2Results posted
• AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's DiseaseCompletedNCT00396201Phase 2Results posted
• AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF AloneTerminatedNCT00395967Phase 2Results posted
• Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma PatientsCompletedNCT00322842Phase 2Results posted
• Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma PatientsCompletedNCT00322491Phase 2Results posted
• Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma PatientsCompletedNCT00322387Phase 2Results posted
• Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological MalignanciesCompletedNCT00241358Phase 1/2Results posted
• Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma PatientsCompletedNCT00103662Phase 3Results posted
• Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma PatientsCompletedNCT00103610Phase 3Results posted
• G-CSF and AMD3100 to Mobilize Stem Cells in Healthy VolunteersCompletedNCT00082329Phase 2Results posted
• AMD 3100 (Mozobil Plerixafor) to Mobilize Stem Cells for DonationCompletedNCT00075335Phase 2Results posted
• Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCTActive, not recruitingNCT06141304Phase 2
• Plerixafor for Poorly Mobilized LymphomaStatus unknownNCT05510544Phase 4
• Plerixafor in Acute Respiratory Distress Syndrome Related to COVID-19 (Phase IIb)WithdrawnNCT05411575Phase 2
• Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-ThalassemiaActive, not recruitingNCT05357482Phase 1/2
• Mobilization of Stem Cells With AMD3100 (Plerixafor) in Combination With G-CSF in Multiple Myeloma PatientsCompletedNCT05087212Phase 4
• Peripheral Blood Stem Cell Collection From Patients With Sickle Cell Disease (SCD) Using PlerixaforWithdrawnNCT04817345Phase 2
• Reduced Intensity Transplantation for Severe Sickle Cell DiseaseActive, not recruitingNCT04362293Phase 2
• AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell CarcinomaWithdrawnNCT04058145Phase 2
• Endometrial Rejuvenation StudyTerminatedNCT04045821Not applicable
• Study Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MGTA-145 in Healthy Volunteers as a Single Agent or in Combination With PlerixaforCompletedNCT03932864Phase 1
• Safety of Blood Stem Cell Mobilization With Plerixafor in Patients With Sickle Cell DiseaseActive, not recruitingNCT03664830Phase 1
• A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell DiseaseCompletedNCT03653247Phase 1/2
• Plerixafor/G-CSF as Additional Agents for Conditioning Before HSCT in CGD PatientsStatus unknownNCT03547830Phase 2
• To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal AdenocarcinomasTerminatedNCT03277209Phase 1
• Low Dose Plerixafor Plus G-CSF in Mobilizing Stem Cells for Autologous Peripheral Blood TransplantationStatus unknownNCT03244930Phase 2
• Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)CompletedNCT03182426Phase 1/2
• Lentiviral-mediated Gene Therapy of Fanconi Anemia Patients Subtype ACompletedNCT03157804Phase 1/2
• Pilot and Feasibility Trial of Plerixafor for Hematopoietic Stem Cell (HSC) Mobilization in Patients With Sickle Cell Disease Pilot and Feasibility Trial of Plerixafor for Hematopoietic Stem Cell (HSC) Mobilization in Patients With Sickle Cell DiseaseCompletedNCT02989701Phase 1
• Clinical Phase II Trial to Evaluate CD34+ Cells Mobilization and Collection in Patients With Fanconi Anemia for Subsequent Transduction With a Lentiviral Vector Carring FANCA Gene. FANCOSTEM-1CompletedNCT02931071Phase 2
• Plerixafor in Diabetic Wound HealingTerminatedNCT02790957Phase 2
• Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor MobilizersWithdrawnNCT02682953Phase 2
• Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and PlerixaforCompletedNCT02678533Phase 1/2
• Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete RemissionStatus unknownNCT02605460Phase 2
• Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)Active, not recruitingNCT02570542Phase 2
• HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV InfectionWithdrawnNCT02343666Phase 1
• Plerixafor Plus Granulocyte Colony-Stimulating Factor For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Non-Hodgkin LymphomaCompletedNCT02221492Phase 2
• Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple MyelomaCompletedNCT02221479Phase 2
• Assessment of Tolerance of Mobilizing Peripheral Hematopoietic Stem Cells by Plerixafor in Sickle Cell PatientsCompletedNCT02212535Phase 1/2
• A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant PairsTerminatedNCT02200380Phase 2
• Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell DiseaseCompletedNCT02193191Phase 1
• To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal CancersCompletedNCT02179970Phase 1
• Stem Cell Mobilization With Plerixafor in Diabetic vs Control SubjectsCompletedNCT02056210Phase 4
• Stem Cell Harvesting Using GCSF Plus Plerxiafor, in First -Line, for Heavily Pre- Treated Pediatric Oncology Patients.Status unknownNCT02006225Phase 4
• Plerixafor as a Salvage Regimen to Mobilize Allogeneic Stem Cells in Healthy VolunteersCompletedNCT01954914Phase 2
• Autologous CD117+ Progenitor Cell Mobilization for Lung TransplantationCompletedNCT01916577Phase 1
• Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous TransplantationCompletedNCT01767714Phase 3
• An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem CellsCompletedNCT01753453Phase 2
• AMD3100 for Sensitizing in Allogeneic Blood or Marrow Transplant for Chemotherapy Resistant Pediatric Acute LeukemiaTerminatedNCT01655875Phase 1
• Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell TransplantationTerminatedNCT01610999Phase 1
• A Phase I Dose Escalation Study of Plerixafor in Healthy Subjects of Japanese DescentCompletedNCT01579149Phase 1
• Treatment of Relapsed or Refractory Acute Myeloblastic LeukemiaCompletedNCT01435343Phase 1/2
• Healthy Donor Study II - Comparing Plerixafor With G-CSF and PlerixaforCompletedNCT01403896Phase 2
• Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)CompletedNCT01352650Phase 1
• Clinical And Economic Impact Of Upfront Plerixafor In Autologous TransplantationCompletedNCT01339572Phase 2
• Gene Therapy for Fanconi AnemiaTerminatedNCT01331018Phase 1

← Plerixafor overview